Webinar Date

Wednesday, June 14, 2017
 Add to Calendar  Add to Calendar
1:00 PM Eastern 12:00 PM Central
11:00 AM Mountain 10:00 AM Pacific

Immunotherapy is an exciting and rapidly growing field in multiple myeloma treatment. Two new immunotherapy drugs (monoclonal antibodies) have been approved for patients with relapsed or refractory myeloma, and others have shown promise in later-stage clinical trials and may be approved soon. To be the best advocates they can be for their own care, myeloma patients need to understand how immunotherapy works, what makes this new treatment approach different, and what patients who receive it can expect. Our new webinar series will address these aspects of immunotherapy, and much more.

Two convenient ways to participate:

  • By phone
  • Online

I would like to register for the following webinar(s):

  Webinar 1 — Monoclonal Antibodies: A New Type of Myeloma Drug
Wednesday, June 14, 2017, 1:00 PM ET
  Webinar 2 — Vaccines for Myeloma (and Other Advances in Immunotherapy)
Wednesday, July 26, 2017, 1:00 PM ET
  Webinar 3 — Engineered Immune Cells
Wednesday, August 9, 2017, 1:00 PM ET

If you are unable to register online or do not receive your confirmation email after registering (don't forget to check your Junk email folder), please contact our Registration Desk at 866-872-5840 (international callers please dial 617-502-2061). You can also contact us by email Send Email

There is no fee for participating in this webinar. To register, please complete the required information and click Submit.

*Indicates required information.

Please note, a registration confirmation will be sent to this email address.

By providing your mobile phone number, you agree to receive a text reminder for this activity. Standard text messaging rates may apply.

Please provide the names and email addresses of additional participants who will be joining you on the webinar.

First name Last name Email


As part of our registration process, we ask you to complete the pre-webinar evaluation below:

1. *How much do you agree with the following statements?

I am knowledgeable about the types of immunotherapy that are currently being studied as possible treatments for multiple myeloma.

I am prepared to discuss immunotherapy as a possible treatment strategy with my healthcare team.

2. Please list a question about multiple myeloma (to be addressed by myeloma experts during the webinars)

Please select a program from the above list.

Powered by BeaconLive